Immunocore Holdings plc (NASDAQ:IMCR) Stock Holdings Trimmed by Polar Capital Holdings Plc

Polar Capital Holdings Plc trimmed its position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 77.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 114,023 shares of the company's stock after selling 387,732 shares during the quarter. Polar Capital Holdings Plc owned 0.23% of Immunocore worth $3,364,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after purchasing an additional 960 shares during the period. NEOS Investment Management LLC raised its holdings in shares of Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after buying an additional 1,102 shares during the period. Virtus ETF Advisers LLC raised its holdings in shares of Immunocore by 39.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock valued at $340,000 after buying an additional 3,238 shares during the period. XTX Topco Ltd raised its holdings in shares of Immunocore by 22.2% during the 4th quarter. XTX Topco Ltd now owns 18,896 shares of the company's stock valued at $557,000 after buying an additional 3,437 shares during the period. Finally, Barclays PLC raised its holdings in shares of Immunocore by 2,044.0% during the 4th quarter. Barclays PLC now owns 20,625 shares of the company's stock valued at $608,000 after buying an additional 19,663 shares during the period. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on IMCR shares. JPMorgan Chase & Co. dropped their target price on Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a report on Monday, April 14th. Mizuho dropped their target price on Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Needham & Company LLC reiterated a "buy" rating and set a $71.00 target price on shares of Immunocore in a report on Thursday, April 10th. Oppenheimer raised their target price on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Finally, HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research note on Wednesday, March 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $58.13.

Insiders Place Their Bets

In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the acquisition, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This trade represents a 60.40% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.40% of the stock is currently owned by company insiders.

Immunocore Stock Down 0.0%

NASDAQ IMCR traded down $0.01 during mid-day trading on Wednesday, reaching $32.39. 156,629 shares of the company's stock traded hands, compared to its average volume of 421,967. Immunocore Holdings plc has a 1-year low of $23.15 and a 1-year high of $53.40. The company has a fifty day simple moving average of $28.87 and a 200-day simple moving average of $30.03. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -34.08 and a beta of 0.75.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.45. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company had revenue of $125.13 million for the quarter, compared to the consensus estimate of $108.82 million. During the same quarter last year, the business posted ($0.49) EPS. Immunocore's quarterly revenue was up 33.6% compared to the same quarter last year. As a group, equities research analysts expect that Immunocore Holdings plc will post -0.94 EPS for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.